EditorialVascular Bioprinting
References (21)
- et al.
The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1—coronary artery bypass grafting surgery
Ann Thorac Surg
(2009) - et al.
Long-term assessment of cryopreserved vein bypass grafting success
J Vasc Surg
(2001) - et al.
The tissue-engineered vascular graft using bone marrow without culture
J Thorac Cardiovasc Surg
(2005) - et al.
Construction of an autologous tissue-engineered venous conduit from bone marrow-derived vascular cells: optimization of cell harvest and seeding techniques
J Pediatr Surg
(2007) - et al.
Tissue-engineered autologous bladders for patients needing cystoplasty
Lancet
(2006) - et al.
Mechanical properties of completely autologous human tissue engineered blood vessels compared to human saphenous vein and mammary artery
Biomaterials
(2009) - et al.
Innovative strategies for tissue engineered skin based on multiple growth factors gene transfection
Med Hypotheses
(2009) - et al.
The ideal graft of the future: a prospect of messianic proportions?
Asian Cardiovasc Thorac Ann
(2009) - et al.
Should saphenous vein grafts be the conduits of last resort for coronary artery bypass surgery?
Cardiol Rev
(2009) - et al.
Addressing thrombogenicity in vascular graft construction
J Biomed Mater Res B Appl Biomater
(2007)
Cited by (6)
3D bioprinting for drug discovery and development in pharmaceutics
2017, Acta BiomaterialiaCitation Excerpt :Compared to other technologies (such as soft lithography, surface patterning, and microfluidic-based manipulation), this powerful technology is a promising method for advancing physiologically-relevant tissue models and microarrays for biomedicine and pharmaceutical applications. Bioprinting technology has been used for the fabrication of a wide variety of 3D tissues including blood vessel [71,72], bone [73], tooth [74], lung [75], kidney [76], liver [77], cardiac [78], cartilage [79], skin [80], heart valve [81], brain [82], nervous [83], pancreas [84], retina [85], tendon [86], trachea vascular [87], composite tissues [88], and cervical tumor models [89]. Bioprinted tissue models for pharmaceutical use are not subject to the rigorous safety, ethical, and regulatory issues that are required for 3D bioprinted organ substitutes for transplantation.
Three-dimensional biofabrication: Our first impressions and its potential in Pediatric Surgery
2020, Cocuk Cerrahisi DergisiA 3D bioprinting system to produce human-scale tissue constructs with structural integrity
2016, Nature BiotechnologyBioprinting: Principles and applications
2015, Bioprinting: Principles and ApplicationsOrgan printing and cell encapsulation
2014, Scaffolds for Tissue Engineering: Biological Design, Materials, and Fabrication
This work was funded by the Cardiovascular Research Review Committee in cooperation with the Baylor Heart and Vascular Institute, Dallas, Texas.